| __timestamp | Amicus Therapeutics, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 19928000 |
| Thursday, January 1, 2015 | 47269000 | 30842000 |
| Friday, January 1, 2016 | 71151000 | 46527000 |
| Sunday, January 1, 2017 | 88671000 | 34451000 |
| Monday, January 1, 2018 | 127200000 | 34409000 |
| Tuesday, January 1, 2019 | 169861000 | 34417000 |
| Wednesday, January 1, 2020 | 156407000 | 145290000 |
| Friday, January 1, 2021 | 192710000 | 298358000 |
| Saturday, January 1, 2022 | 213041000 | 488691000 |
| Sunday, January 1, 2023 | 275270000 | 468946000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, managing costs is crucial for survival and growth. Amicus Therapeutics, Inc. and Novavax, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amicus Therapeutics saw a steady increase in SG&A expenses, peaking at approximately 275% of their 2014 levels by 2023. This reflects their strategic investments in expanding operations and market reach. Meanwhile, Novavax, Inc. experienced a more volatile journey, with a dramatic surge in expenses, especially post-2020, reaching nearly 470% of their 2014 levels by 2023. This spike aligns with their aggressive push in vaccine development during the pandemic era. Understanding these trends offers valuable insights into how these companies navigate financial challenges and opportunities in the biotech sector.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared